Hypocretin/Orexin Interactions with Norepinephrine Contribute to the Opiate Withdrawal Syndrome

Ronald McGregor,1,2 Ming-Fung Wu,1,2 Brent Holmes,2,4 Hoo Anh Lam,1,8 Nigel T. Maidment,1,3,8 Joseph Gera,2,4,5,6 Akihiro Yamanaka,7 and Jerome M. Siegel1,2,3

1Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California 90095, 2Veterans Administration Greater Los Angeles Healthcare System, North Hills, Los Angeles, California 91343, 3Brain Research Institute, University of California, Los Angeles, Los Angeles, California 90095, 4Department of Medicine, University of California, Los Angeles, Los Angeles, 90095, 5Johnson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, 90095, 6Molecular Biology Institute, University of California, Los Angeles, Los Angeles, 90095, 7Department of Neuroscience II, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan, and 8Hatos Center for Neuropharmacology, University of California, Los Angeles, Los Angeles, California 90095

We previously found that human heroin addicts and mice chronically exposed to morphine exhibit a significant increase in the number of detected hypocretin/orexin (Hcrt)-producing neurons. However, it remains unknown how this increase affects target areas of the hypocretin system involved in opioid withdrawal, including norepinephrine containing structures locus coeruleus (LC) and A1/A2 medullary regions. Using a combination of immunohistochemical, biochemical, imaging, and behavioral techniques, we now show that the increase in detected hypocretin cell number translates into a significant increase in hypocretin innervation and tyrosine hydroxylase (TH) levels in the LC without affecting norepinephrine-containing neuronal cell number. We show that the increase in TH is completely dependent on Hcrt innervation. The A1/A2 regions were unaffected by morphine treatment. Manipulation of the Hcrt system may affect opioid addiction and withdrawal.

Key words: addiction; anatomy; hypocretin; locus coeruleus; opioids; withdrawal

Significance Statement

Previously, we have shown that the hypothalamic hypocretin system undergoes profound anatomic changes in human heroin addicts and in mice exposed to morphine, suggesting a role of this system in the development of addictive behaviors. The locus coeruleus plays a key role in opioid addiction. Here we report that the hypothalamic hypocretin innervation of the locus coeruleus increases dramatically with morphine administration to mice. This increase is correlated with a massive increase in tyrosine hydroxylase expression in locus coeruleus. Elimination of hypocretin neurons prevents the tyrosine hydroxylase increase in locus coeruleus and dampens the somatic and affective components of opioid withdrawal.

Introduction

We (Mileykovskiy et al., 2005; McGregor et al., 2011; Wu et al., 2011a,b; Blouin et al., 2013) and others (Nestler et al., 2002; Georgescu et al., 2003; Harris et al., 2005; Boutrel and de Lecea, 2008; Borgland et al., 2009; Aston-Jones et al., 2010; Nestler, 2013; Baimel et al., 2015; James et al., 2017) have shown that hypocretins/orexins (Hcrt) play a key role in processing rewards. Recently, we reported that the number of detectable Hcrt neurons is greatly increased in human heroin addicts as well as in mice administered daily injections of morphine for 2 weeks (Thannickal et al., 2018; Donjacour et al., 2019). It was then shown that chronic exposure to cocaine produced a similar increase in the number of detected Hcrt neurons in rats (James et al., 2019). These findings suggest a major role of Hcrt plasticity in the addictive process. However, it remains unknown how target areas of the Hcrt system that are critically related to opioid addiction, including norepinephrine (NE) containing locus coeruleus (LC) and the NE-containing A1/A2 medullary nuclei (Christie et al., 1997; Peyron et al., 1998; Delfs et al., 2000; Blanco-Centurion et al., 2007; Sharf et al., 2008; Valentino and Van Bockstaele, 2008; Mazei-Robinson and Nestler, 2012; Parkitna et al., 2012; Chaijale et al., 2013; Jaremko et al., 2014; Keidi et al., 2015; Zhang et al., 2017; Soleciki et al., 2019), are affected by the increase in the number of detected Hcrt neuronal
somas. We now find that chronic morphine administration greatly increases Hcrt projections to the LC. In contrast no increase is seen in the A1/A2 areas. Morphine treatment greatly increases tyrosine hydroxylase (TH) expression in LC. We find that this increase is completely dependent on Hcrt innervation. Hcrt removal did not affect acquisition of morphine conditioned place preference (CPP) but prevented locomotor sensitization to repeated drug administration. Hcrt depletion significantly reduced the physical withdrawal symptoms induced by naloxone and the aversion to a chamber associated with naloxone in morphine-dependent animals. These findings may explain the minimal drug withdrawal effects and the low rate of drug addiction seen in narcoleptic humans, a disease caused by the loss of Hcrt neurons. They also support a role for Hcrt antagonists in treating opiate addiction.

Materials and Methods

Subjects

Animal usage. All procedures were approved by the Institutional Animal Care and Use Committees of the University of California, Los Angeles, and of the Veterans Administration Greater Los Angeles Health Care System.

Animals. Experiments were performed in genetically modified C57BL/6 mice expressing diphtheria toxin fragment A (DTA) exclusively in Hcrt neurons (DTA-Hcrt) under the control of the Tet-Off system. In these animals, postnatal ablation of Hcrt neurons can be induced by doxycycline withdrawal, as previously described (John et al., 2013; Tabuchi et al., 2014). Complete ablation of Hcrt neurons was accomplished in one group of animals (depleted-DTA-Hcrt) by removing doxycycline from the diet for 30 d beginning at 42 d of age, after which doxycycline-containing feed was resumed. Control animals (intact-DTA-Hcrt) were maintained throughout the study on the diet containing doxycycline. A total of 140 male mice were used in the current study (Table 1 shows the number of animals in each experiment). All experimental procedures were started when animals reached 3 months of age. Animals were kept in a room maintained at 22 ± 1°C on a 12 h light (45 lux)/dark (0.03 lux) cycle, with lights on at 7:00 A.M. [zeitgeber time 0 (ZT0)] and lights off at 7:00 P.M. (ZT12).

Drugs

Morphine (morphine sulfate, Hospira) and naloxone (naloxone hydrochloride dihydrate; catalog #N7758, Millipore Sigma) were used. Morphine and naloxone were dissolved in sterile saline immediately before subcutaneous administration.

Behavioral studies

Sensitization to morphine. Locomotor activity was monitored using digital video recordings. Briefly, cameras (Analog HD 1080p, LBV2723, Lorex Technology, Canada) were suspended above modified laboratory cages (40 × 20 × 50 cm). Animals were placed in the cages and allowed 14 d of acclimation under continuous video recording. After this initial period, morphine (50 mg/kg, s.c.) or saline (subcutaneous) was administered. This experiment was performed to establish whether our single fixed daily dose of morphine injection for 14 d generates comparable somatic signs of opioid withdrawal to escalating morphine doses (see Results). All sessions were conducted in Plexiglas cages. We quantified locomotion, jumping, backward stepping, rearing, paw tremor, teeth chattering, grooming, behavioral arrest, defecation, urination, wet dog shake, ptosis, diarrhea, body tremor, and piloerection. A global withdrawal score was calculated (Maldonado et al., 1996; Georgescu et al., 2003; Shaf et al., 2008; Zhang et al., 2016). Two hours after naloxone administration, animals were killed and processed for immunohistochemistry (see below).

Naloxone conditioned place aversion. Place conditioning took place in square chambers (26 × 26 × 19.5 cm) with infrared photobeam sensors that allowed for automated recording of subject location (time spent in each chamber) and locomotor activity (TruScan, Coulbourn Instruments). The chambers were divided into two smaller chambers of equal size (26 × 13 × 19.5 cm) by a Plexiglas partition. One of these chambers contained white walls with black dots (diameter, 1.5 cm), a dark metal floor with large punched circles (diameter, 0.5 cm), and 20 µl of lemon liquid extract (McCormick) placed on a slip of paper taped to the top of the chamber. The other chamber contained blue walls, a silver metal floor with small punched circles (diameter, 0.3 cm), and 120 µl of almond liquid extract (McCormick) placed on a slip of paper taped to the top of the chamber. For the 15 min preconditioning and postconditioning test sessions, the center divider was replaced with a similar divider that incorporated a small opening in the bottom (5 × 5 cm). At the start of all conditioning and testing sessions, animals were placed directly in the front left corner of the predetermined chamber. A computer running TruScan software controlled all experimental events and recorded behavioral data.

Table 1. Number of animals used in each experimental procedure

<table>
<thead>
<tr>
<th>Experiment</th>
<th>Animals, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>LC quantification of immunofluorescence</td>
<td>16</td>
</tr>
<tr>
<td>TH quantification of TH cell number</td>
<td>12</td>
</tr>
<tr>
<td>A1/A2 quantification of immunofluorescence</td>
<td>12</td>
</tr>
<tr>
<td>A1/A2 quantification of TH cell number</td>
<td>8</td>
</tr>
<tr>
<td>Western blots</td>
<td>12</td>
</tr>
<tr>
<td>Conditioned place preference</td>
<td>24</td>
</tr>
<tr>
<td>Sensitization</td>
<td>12</td>
</tr>
<tr>
<td>Withdrawal from escalating vs fixed morphine dose</td>
<td>12</td>
</tr>
<tr>
<td>Naloxone-precipitated withdrawal</td>
<td>12</td>
</tr>
<tr>
<td>Naloxone aversion</td>
<td>20</td>
</tr>
</tbody>
</table>

The table depicts the number of animals used for each experimental procedure.
Drug treatment and conditioning. On days 1–5, mice received a single daily injection of escalating doses of morphine in the home cage (ZT3: 10, 20, 30, 40, 50 mg/kg, s.c.). On day 6, 20 h after the last morphine injection (50 mg/kg, s.c.), mice were injected with saline and immediately placed in one of the two chambers (saline-paired chamber) for 30 min. Upon returning to their home cages, animals received a subsequent dose of morphine (50 mg/kg, s.c.). On day 7, 20 h after the morphine injection, animals received either 0.05 or 0.2 mg/kg (s.c.) naloxone and were immediately placed in the alternate side of the chamber (naloxone-paired chamber) for 30 min. Upon return to their home cages, animals received another dose of morphine (50 mg/kg, s.c.). This conditioning procedure was repeated on consecutive days in an alternating fashion such that each animal was exposed to 3 d of saline and 3 d of naloxone conditioning. On the subsequent test day, 20 h after the final morphine dose, animals were allowed free access to both chambers for 15 min and the time spent in each chamber was recorded.

For this experiment, an unbiased design was used, with assignment of saline- and naloxone-paired chambers being made on the basis of pre-test conditioning data to ensure a balance between time spent in future saline-paired versus future naloxone-paired chambers within and across groups. An aversion score was calculated by subtracting the time spent in the naloxone-paired chamber from time spent in the saline-paired chamber during the postconditioning test.

Western blot. All animals were killed between ZT5 and ZT7. Animals were deeply anesthetized with pentobarbital (Nembutal, 100 mg/kg, i.p.) and decapitated. Brains were quickly removed from the skull, and the locus coeruleus was dissected. Tissue was then sonicated in lysis buffer containing 50 mM Tris HCl, 50 mM MgCl2, 5 mM EDTA, and protease inhibitor tablet (catalog #12482000, Roche); and centrifuged at 10,000 g (3000 rpm) for 30 min at 4°C. The protein concentration of the supernatant was determined using the DC Protein Assay Kit (catalog #500–0112, Bio-Rad). Forty micrograms of protein was loaded on a 12% Mini-PROTEAN TGX Precast Gel (catalog #456–1044, Bio-RAD), and separated at 50 V. The proteins were then transferred to a PVDF membrane (catalog #162–0176, BIO-RAD) at 50 mA for 120 min. The membrane was washed in 20 mM Tris, 150 mM NaCl, and 0.1% Tween 20 (TBST), and then blocked in TBST containing 5% (w/v) nonfat dry milk (NFDM) for 60 min. The membrane was incubated with rabbit anti-TH antibody (1:1000; catalog #2792, lot #6, Cell Signaling Technology) in 5% NFDM in TBST overnight at 4°C. The next day, the membrane was washed in TBST before incubation with donkey anti-rabbit HRP-conjugated secondary antibody (1:10,000; catalog #NA934V, lot #16963367, GE Healthcare Life Sciences) at a dilution of in 5% NFDM in TBST, for 60 min at room temperature. After washing in TBST, the antibody complex was visualized with SuperSignal West Femto (catalog #34094, Thermo Fisher Scientific). Anti-β-actin (1:10,000; catalog #A2282, lot #099M4776V, Sigma-Aldrich) was used as an internal normalizer, with sheep anti-mouse HRP-conjugated secondary antibody (1:10,000; catalog #NA913V, lot #16814909, GE Healthcare Life Sciences). The densities of TH and β-actin bands for each sample were measured using ImageJ software.

Statistical analysis

Data were subjected to either ANOVA followed by Tukey’s post hoc test comparisons, or t test. All such tests were two tailed. Results were considered statistically significant at p < 0.05. The number of subjects in each experimental procedure is indicated by degrees of freedom.

Results

Anatomy

Morphine treatment increases Hcrt axonal labeling in the LC

We observed a significant increase of 52.3% in Hcrt staining in the LC of animals injected with morphine, compared with animals injected with saline (Fig. 1a; p = 0.022, df = 6, t test). This increase in immunofluorescence intensity was linked to a significant increase (201.4%) in the number of Hcrt-immunopositive fibers per unit of area (Hcrt fiber density) in the LC (Fig. 1b; p = 0.0044, df = 6, t test).
Morphine treatment increases TH levels and immunofluorescence intensity in the LC without increasing the number of labeled cells, dependent on Hcrt innervation

We observed a significant increase (69.9%) in the levels of TH in the LC, as illustrated in the Western blot assay shown in Figure 2, a (top) and.create a (p = 0.035, df = 10, t test). This change was associated with a significant (80.1%) increase in the intensity of TH immunofluorescence in LC after morphine treatment (Fig. 2c; p = 0.029, df = 6, t test), establishing a relation between TH levels and TH immunofluorescence intensity. The increase in TH levels detected in the LC after morphine treatment was not the result of an increase in the number of TH-expressing neurons in this structure (Fig. 2d). Rather, individual neurons showed a higher concentration of the enzyme, as illustrated in the confocal images (Fig. 2e) of representative sections of the LC in an animal treated with saline (Fig. 2e, left) and morphine (Fig. 2e, middle). When Hcrt innervation was eliminated (depleted-DTA-Hcrt) before the 2 week daily injection of 50 mg/kg morphine, there was no difference in the TH immunofluorescence intensity between morphine-treated animals and saline controls (Fig. 2e, right,f) indicating that Hcrt neurons are necessary for the morphine-induced increase in LC TH levels (Fig. 2e, f, scale bar, 100 μm). Lack of Hcrt did not affect the number of TH⁺ neurons after morphine treatment compared with saline- and morphine-treated animals (Fig. 2g).

Morphine treatment does not alter Hcrt axon density or TH levels in the A1/A2 medullary norepinephrine-containing regions

It has been proposed that medullary NE cell groups A1 and A2, acting through their projections to the ventral bed nucleus of the stria terminalis, are critical in withdrawal behavior, rather than LC (Delfs et al., 2000; Fox et al., 2016). In the current study, we found that Hcrt innervation and TH levels of the A1 and A2 medullary NE nuclei were unaffected by morphine treatment (Fig. 3a–d) in mice in which the Hcrt system was intact (intact-DTA-Hcrt). Furthermore, deletion of Hcrt neurons did not affect the number of TH⁺ neurons in the A1 or A2 regions (Fig. 3e,f). Depleted-DTA-Hcrt mice treated with morphine did not show significant changes to the TH levels in either of these medullary NE regions compared with animals with the full contingent of Hcrt neurons (intact-DTA-Hcrt) treated with saline or morphine (Fig. 3g,h). Representative examples of low-magnification confocal images of the A1 (Fig. 3i) and A2 (Fig. 3j) medullary regions of an intact-DTA-Hcrt animal treated with saline showing the distribution of TH⁺ cell bodies in red (yellow arrows) and Hcrt fibers in green (white arrowheads). The insert in Figure 3j shows a higher magnification of the white rectangle (scale bars: 100 μm; insert, 20 μm).

Behavior

The rewarding properties of morphine as measured herein are not significantly affected by the lack of Hcrt neurons. But Hcrt depletion prevents locomotor sensitization and reduces both the somatic signs of naloxone-precipitated withdrawal and naloxone conditioned place aversion (CPA) in morphine-dependent animals.

Intact-DTA-Hcrt and depleted-DTA-Hcrt animals both developed CPP to morphine (Fig. 4a). However, locomotor sensitization to repeated drug administration was significantly 

seen in the confocal images in Figure 1, c (saline) and d (morphine), taken at the same anterior-posterior level. Inserts show the area outlined within the white square at higher magnification, illustrating the increase in fiber density. Figure 1, e and f, show fiber tracings of the circumscribed area outlined in yellow for each condition (scale bars: yellow, 100 μm; insert, 20 μm; black, 100 μm). We did not observe a significant difference in the distribution of Hcrt fiber density between the LC areas analyzed under the saline condition (dorsal, 6.87 ± 0.64; vs lateral, 8.12 ± 0.94; p = 0.316, df = 6, t test; lateral, 7.88 ± 0.47; vs medial, 7.61 ± 0.81; p = 0.78, df = 6, t test) or after morphine (dorsal, 14.15 ± 1.03; vs lateral, 15.95 ± 1.06; p = 0.269, df = 6, t test; lateral, 14.54 ± 1.05; vs medial, 15.54 ± 0.7; p = 0.46, df = 6, t test).
Morphine treatment increases TH immunofluorescence intensity in the LC without increasing the number of labeled cells. This effect is dependent on Hcrt innervation. **a,** Top, Western blot assay showing a significant increase (69.9%) in the levels of TH in intact-DTA-Hcrt animals treated with morphine (14 d, 50 mg/kg, s.c.) compared with saline animals (left, saline; right, morphine; n = 6/condition). **b,** Relative density of bands expressed as the ratio of TH and β-actin in animal groups. **c,** Elevation of TH levels was reflected in a significant increase in the TH immunofluorescence intensity per unit of area (80.1%) compared with saline in the LC (n = 4/condition). **d,** No significant difference in the number of TH-expressing cells in the LC in animals treated with morphine compared with saline was observed (n = 4/condition). **e,** Confocal images of representative sections of the LC of intact-DTA-Hcrt animals after saline (left) or morphine (middle) treatment. The difference in TH immunofluorescence is visually recognizable. When Hcrt neurons were depleted (right), there was no difference in TH immunofluorescence between animals injected with morphine and animals injected with saline (n = 4/condition). **f,** Group data showing no significant difference in TH labeling in depleted-DTA-Hcrt mice given saline and depleted-DTA-Hcrt mice given 14 d of 50 mg/kg morphine. **g,** There is no significant difference in the number of TH-expressing cells in the LC of mice lacking Hcrt neurons and treated with morphine compared with intact animals treated with saline or morphine (n = 4/condition). Scale bar, 100 μm. *p = 0.029, **p = 0.035.

**Discussion**

We have reported that the brains of human heroin addicts and of mice exposed to opioids present a substantially higher number of Hcrt-immunopositive neurons compared with controls (Thannickal et al., 2018). We speculate that the elevation of Hcrt levels may result from the excitatory effects of morphine on Hcrt neurons *in vivo* that we previously reported (Thannickal et al., 2018). We now show that this hypothalamic anatomic change induced by morphine also produces a significant increase in the Hcrt axonal presence in the LC, a NE-containing structure involved in the modulation of opioid withdrawal (Christie et al., 2018).
In addition, we observed that morphine treatment induced a significant increase in the levels of the TH enzyme, the rate-limiting step in the synthesis of NE (Kobayashi and Nagatsu, 2005) in this structure, and that this increase is entirely dependent on Hcrt. In contrast, we observed that Hcrt innervation and TH levels in the A1 and A2 medullary NE regions, structures also reported to affect opioid withdrawal behaviors (Delfs et al., 2000), were unaffected by morphine treatment.

In the current studies, we found that mice lacking Hcrt neurons (DTA-depleted) did not develop sensitization to repeated doses of morphine and displayed a reduction in the somatic and affective symptoms of withdrawal following naloxone administration in dependent animals.

Morphine exposure results in an increased Hcrt axon density in the LC but not in the A1 and A2 medullary regions

The increase in the number of detectable Hcrt neurons in the hypothalamus we have previously reported after morphine exposure is the result of augmented Hcrt peptide production in neurons that were not producing detectable levels of Hcrt under baseline conditions, not neurogenesis (McGregor et al., 2017; Thannickal et al., 2018). We now show that this increment in Hcrt peptide production is correlated with a significant increase in the number of detectable Hcrt axons in the LC, the brainstem structure receiving the largest Hcrt projections under baseline conditions (Peyron et al., 1998; Puskás et al., 2010). Most likely, Hcrt axons are present in the LC, but remain undetectable under baseline conditions. However, we cannot dismiss the possibility that axonal growth occurs as a result of morphine treatment.

On the other hand, the A1/A2 medullary regions, which also receive dense Hcrt projections (Puskás et al., 2010), did not show a significant increase in the number of detectable Hcrt axons after morphine treatment of intact-DTA-Hcrt mice, indicating that the increase in Hcrt innervation is region specific. Prior work has reported that disruption of A1/A2 NE transmission reduces only the affective component of opioid withdrawal (Delfs et al., 2000). In the present report, we show that the disruption of Hcrt transmission results in the reduction of both physical and affective symptoms of opioid withdrawal, suggesting a possible synergistic participation of the LC and A1/A2 in the opiate withdrawal syndrome.

The presence of Hcrt in the LC is necessary for the increase in the levels of TH in this structure after chronic opiate administration, since depletion of Hcrt neurons completely eliminated this change. A previous study reported that brain-derived neurotrophic factor from outside the LC is also critical for the increase in TH levels seen in this structure after morphine exposure (Akbarian et al., 2002). In contrast to the robust increase in the number of detected Hcrt neurons after opioid (Thannickal et al., 2018) or cocaine (James et al., 2019) administration, we do not see an increase in the number of TH+ neurons in the LC or A1/A2 regions after opiate administration.
Hcrt neurons, opiate reward, physical withdrawal, and conditioned aversion to opiate receptor blockade

In the current study, consistent with prior reports in Hcrt peptide knock-out mice, in which the Hcrt peptide is eliminated but the neurons remain (Sharf et al., 2010), we observed that mice in which Hcrt neurons were eliminated (depleted-DTA-Hcrt) develop a preference for the chamber previously paired with morphine at the same rate as intact-DTA-Hcrt animals, indicating that the lack of Hcrt neurons does not affect the rewarding properties of morphine. On the other hand, elimination of Hcrt neurons completely blocked locomotor sensitization to repeated doses of morphine, a response that develops in intact animals repeatedly exposed to morphine. This is in agreement with prior studies using a dual Hcrt receptor antagonist to block Hcrt transmission (Georgescu et al., 2003; Sharf et al., 2008; Laorden et al., 2012). Drug sensitization may correlate with the enhanced pleasure experienced by addicts with repeated drug injections (Robinson and Berridge, 1993; Kalivas and Volkow, 2005; Chefer and Shippenberg, 2009; Berridge and Kringelbach, 2013). The absence of this behavior in animals lacking Hcrt neurons parallels the finding in human narcoleptic patients, characterized by an average loss of 90% of Hcrt neurons (Thannickal et al., 2000), who show little, if any, evidence of drug abuse and addiction (Borgland et al., 2009; Brown and Guilleminault, 2011; Guilleminault and Fromherz, 2011; James et al., 2017), despite their daily prescribed use of $\gamma$-hydroxybutyrate (GHB), methylphenidate, and amphetamine, drugs frequently abused in the general population (Harris et al., 2007; Borgland et al., 2009;
Nishino and Mignot, 2011; Dauvilliers et al., 2013; Barateau et al., 2016; Jalal et al., 2018; Turner et al., 2018; Darke et al., 2019. Dose escalation and overdose are virtually nonexistent in narcoleptic patients (Galloway et al., 1997; Aston-Jones et al., 2010; Bayard and Dauvilliers, 2013; Baimel et al., 2015). Also, narcoleptics do not experience withdrawal when they take “drug holidays,” from prescribed amphetamines or GHB (Brown and Guilleminault, 2011; Cao and Guilleminault, 2011). In addition, consistent with this and with prior animal studies (Georgescu et al., 2003; Sharff et al., 2008; Laorden et al., 2012), we observed that Hcrt-depleted mice displayed both a dampened physical response to naloxone-precipitated withdrawal when morphine dependent, and a lack of a CPA to a low dose of naloxone that does not precipitate physical withdrawal, indicating that the Hcrt system is involved in the modulation of both physical and affective components of withdrawal.

These results suggest that part of the mechanisms underlying the behavioral difference in response to naloxone withdrawal between intact-DTA-Hcrt and depleted-DTA-Hcrt morphine-dependent animals can be found in the lack of TH increase in the LC in animals lacking Hcrt neurons. Since TH is the rate-limiting step in the synthesis of NE (Kumer and Vrana, 1996), we hypothesize that the upregulation of this enzyme observed in animals with a full contingent of Hcrt neurons (intact-DTA-Hcrt) may increase the capacity of these neurons to produce NE, which in turn may lead to changes in the amounts of neurotransmitter released in the terminal fields. Because of the extensive projections of the LC throughout the neuraxis, altered NE levels in target regions may significantly impact the physiology of a plethora of systems, including those that regulate arousal, anxiety, and stress (Berridge and Waterhouse, 2003; Ross and Van Bockstaele, 2020), contributing to the effects of opioid withdrawal.

Together, the results of the current study open new possibilities for the treatment of opioid withdrawal through pharmacological modulation of the Hcrt system.

References


